Brain health in multiple sclerosis

A nursing resource

Jodi Haartsen
Aliza Ben-Zacharia
Helmut Butzkueven
Kathleen Costello
Suhayl Dhib-Jalbut
Gavin Giovannoni
June Halper
Jeremy Hobart
Gisela Kobelt
Vicki Matthews
George Pepper
Maria Pia Sormani
Christoph Thalheim
Anthony Traboulsee
Timothy Vollmer



MS Brain Health activities and supporting materials have been funded by grants from AbbVie, Actelion Pharmaceuticals and Sanofi Genzyme, and by educational grants from Biogen, F. Hoffmann-La Roche, Merck KGaA and Novartis, all of whom had no influence on the content

This guide explains how nurses can put into practice the recommendations from the report *Brain health: time matters in multiple sclerosis*, which can be found at www.msbrainhealth.org/report.

The recommendations from *Brain health: time matters in multiple sclerosis* have been endorsed by the following organizations (as at the end of April 2017):

- Accelerated Cure Project for Multiple Sclerosis
- ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis)
- American Association of Neuroscience Nurses
- BCTRIMS (Brazilian Committee for Treatment and Research in Multiple Sclerosis)
- Consortium of Multiple Sclerosis Centers
- Czech Multiple Sclerosis Society (Unie ROSKA)
- ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis)
- European Brain Council
- European Multiple Sclerosis Platform
- Francophone Multiple Sclerosis Society (Société Francophone de la Sclérose en Plaques)
- International Multiple Sclerosis Cognition Society
- International Organization of Multiple Sclerosis Nurses
- International Society of Neuroimmunology
- Italian Multiple Sclerosis Association (Associazione Italiana Sclerosi Multipla)
- Japan Multiple Sclerosis Society
- LACTRIMS (Latin-American Committee for Treatment and Research in Multiple Sclerosis)
- MENACTRIMS (Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis)
- MexCTRIMS (Mexican Committee for Treatment and Research in Multiple Sclerosis)

- Multiple Sclerosis Association of America
- Multiple Sclerosis Association of Kenya
- Multiple Sclerosis Australia
- Multiple Sclerosis Coalition
- Multiple Sclerosis Foundation (USA and Puerto Rico)
- Multiple Sclerosis International Federation
- Multiple Sclerosis Ireland
- Multiple Sclerosis Research Australia
- Multiple Sclerosis Society (UK)
- Multiple Sclerosis Society of Canada
- Multiple Sclerosis Society Malaysia
- Multiple Sclerosis Spain (Esclerosis Múltiple España)
- Multiple Sclerosis Trust (UK)
- National Multiple Sclerosis Foundation of the Netherlands (Nationaal MS Fonds)
- National Multiple Sclerosis Society (USA)
- Norwegian Multiple Sclerosis Federation (Multippel Sklerose Forbundet)
- PACTRIMS (Pan-Asian Committee for Treatment and Research in Multiple Sclerosis)
- RIMS (European Network for Rehabilitation in Multiple Sclerosis)
- RUCTRIMS (Russian Committee for Treatment and Research in Multiple Sclerosis)
- Shift.ms
- Swedish Neurological Association (Neuroförbundet)
- UK Multiple Sclerosis Specialist Nurse Association
- The Work Foundation (UK)

About this guide

This concise guide to brain health in multiple sclerosis (MS) is a resource for nursing professionals. It explains how nurses can put into practice the recommendations from the report *Brain health*: time matters in multiple sclerosis.

This guide and the report are authored by an international multidisciplinary group, including specialist nurses, clinicians, researchers, health economists, people with MS and representatives from patient organizations. We recommend a therapeutic strategy (**Figure 1**) that involves:

- an understanding of the importance of brain health at all stages of the disease (pages 2–3)
- a brain-healthy lifestyle (page 4)
- informed, shared decision-making (pages 5–6)
- early treatment with a disease-modifying therapy (DMT), when appropriate (pages 5–6)
- strategies to monitor and assess treatment effectiveness (pages 7–8).




Figure 1. Overview of a therapeutic strategy based on regular monitoring that aims to maximize lifelong brain health while generating robust real-world evidence.

DMTs, disease-modifying therapies.

Nurses play a key role in the care and support of people with MS

"My MS nurse is my lifeline. Without her I would be lost. She gives me as much or as little as I request."

Nurses with specialist knowledge of MS play a pivotal role within MS clinical services, which includes:

- provision of education and information about MS, DMTs and wellness strategies
- support and counselling
- implementation of DMT safety and effectiveness monitoring programmes
- symptom assessment and management
- case management and clinical care.

This guide includes suggestions for how you can implement relevant recommendations from the *Brain health: time matters in multiple sclerosis* report in your clinical practice.

The brain health perspective on MS

In MS, the body produces an immune response against its own tissue in the brain, spinal cord and optic nerves, causing inflammation, destruction of myelin and nerve degeneration. This results in long-term damage that can cause physical disability, fatigue, cognitive impairment and emotional problems. Even at low levels of physical disability, MS may lead to considerable personal and societal costs, and these costs increase as disability progresses. Therefore, there is a strong individual and global health economic argument for maintaining brain health in people with MS.

The range of symptoms experienced by people with MS varies, depending on the locations of tissue damage in the central nervous system. Areas of intensive tissue damage (lesions) can noticeably disrupt nerve function and lead to clinical attacks (relapses), with new symptoms and impairments or worsening of existing ones. However, many new lesions occur without associated clinical symptoms. As people age, it is normal to lose small amounts of brain tissue (referred to as 'brain volume loss' or 'brain atrophy'); however, this process happens more quickly in people with MS than in healthy adults (**Figure 2a**). Even in the absence of clinical symptoms and relapses, it is thought that all lesions may contribute to long-term functional changes and accelerated brain atrophy. In the long term, tissue loss in MS – in lesions and the whole brain – leads to an increase in disability and in the severity and number of symptoms.

The brain is a remarkably flexible organ; it can recruit new areas to allow acquisition of new skills or to compensate for damage. When MS causes damage to brain tissue in one area, new areas are often recruited to help with the tasks previously performed by the damaged area.^{4,5} The capacity of the brain to adapt in this way is known as **neurological reserve** – this correlates with brain volume – and the more neurological reserve a brain has, the healthier it is (**Figure 2b**).

Time is critical

It is now known that MS can be active even when someone is feeling well. Research has shown that only about one in ten lesions (as detected by magnetic resonance imaging [MRI]) leads to a relapse (**Figure 2c**),^{6,7} and that other, less noticeable, damage can also be ongoing, without clinical symptoms occurring.⁸ So, although a person with MS may be asymptomatic, the rate of brain atrophy can be accelerated and neurological reserve may be depleted to compensate for subclinical damage. As neurological reserve is depleted, the capacity of the brain to recruit new areas decreases and the symptoms of MS and associated disability are more likely to progress (**Figures 2d, 2e**).

Neurological reserve is a valuable resource that plays a large part in having a healthy, well-functioning brain. Intervention should aim to maximize the brain health and physical functioning of each individual with MS. This guide gives further information on how you can contribute to helping people with MS maximize their lifelong brain health.

- **Educate colleagues and people with MS** about why neurological reserve and brain health are important.
- Provide prompt support for people with suspected or newly diagnosed MS, and for those who are living with a diagnosis of MS.




Figure 2. The damage caused by MS typically leads to relapses followed by progressive disease.

a. The brains of people with MS atrophy more rapidly than those of healthy people as a result of damage caused by the disease. **b.** The brain can use its neurological reserve to compensate for damage by remodelling itself. However, when its neurological reserve is depleted, the clinical symptoms of the disease may progress.

c. MS causes lesions – acute areas of damage to the brain and spinal cord that accumulate over time. If a lesion noticeably disrupts nerve function, it leads to a relapse (an attack of clinical symptoms). **d.** A typical MS disease course involves relapses, followed by progressive disease, which may involve progression of physical disability and cognitive decline. **e.** Disease-modifying therapies are most effective in the early stages of the disease when relapses, new lesion accumulation and inflammation are still present. Therefore, early intervention with disease-modifying therapies is key to improving outcomes for people with MS.

CIS, clinically isolated syndrome; NRSPMS, non-relapsing secondary progressive multiple sclerosis; RIS, radiologically isolated syndrome; RRMS, relapsing–remitting multiple sclerosis.

Positive lifestyle choices can help to maximize lifelong brain health

Treating and managing MS requires a comprehensive approach. The following lifestyle factors can contribute to maximizing lifelong brain health in people with MS, whatever their MS diagnosis.



Avoiding smoking

Cigarette smoking is associated with decreased brain volume in people with MS,⁹ as well as with higher relapse rates,¹⁰ increased disability progression,^{10,11} more cognitive problems¹² and reduced survival,¹³ compared with not smoking.



Cardiovascular fitness

Higher levels of aerobic fitness are associated with faster information processing and preserved brain tissue volume;¹⁴ therefore, aerobic exercise should be a part of managing MS.



Maintaining a healthy weight

Being overweight or obese is associated with an increased lesion burden compared with maintaining a healthy weight.⁹



Intellectually enriching activities

Education, reading, hobbies and artistic or creative pastimes help to protect against cognitive problems in MS when pursued over a lifetime. 15-19



Limiting alcohol

Alcohol abuse is associated with reduced survival in people with MS.¹³



Minimizing comorbidities

Conditions such as high blood pressure, high cholesterol, heart disease and diabetes can worsen the MS disease course. 9,20,21

- **Educate people with MS about the importance of maximizing lifelong brain health** with positive lifestyle measures.
- Provide people with MS with written information to support discussion and enable gradual learning. You can download a one-page summary of the lifestyle guidance above at www.msbrainhealth.org/resources/article/six-ways-to-lead-a-brain-healthy-lifestyle.
- **Encourage people with MS to adopt and maintain a brain-healthy lifestyle** and assist them in developing practical strategies for their individual circumstances.
 - □ In particular, MS nurses can work collaboratively with people with MS and their primary care physicians or other healthcare professionals to minimize comorbidities and promote adherence to management plans.
- **Empower people with MS by providing relevant information about local support**, such as smoking cessation services, exercise classes, weight loss groups and guidance from a dietitian.

Nurses can help to empower people with MS

Being diagnosed with a chronic, unpredictable, progressive incurable disease can cause distress and impose substantial personal costs on both the individual with MS and their family. MS-related cognitive impairment, depression, anxiety and fatigue are common and may be present with or without more obvious clinical symptoms. Nurses are well placed to establish trust and rapport, and to provide support and counselling for people with MS.

When people with MS have good, open, trust-based relationships with healthcare professionals^{22,23} and feel well informed about their disease and its treatment,²⁴ they are more likely to continue with their treatment – and therefore are less likely to experience serious relapses.²⁵ Hence, a well-informed and proactive collaboration between people with MS and their healthcare professionals is an important part of managing MS successfully.

What can you do in your nursing practice?

- **Educate people with MS about their disease**, about their role in shared decision-making and about the impact that their choices may have on their brain health.
- **Empower people with MS to participate in decisions** about their treatments and healthcare.
- **Educate people with MS about the importance of maximizing their lifelong brain health** by making positive lifestyle choices, as well as taking appropriate drug treatments.

Early intervention with a DMT can reduce disease activity

In people with relapsing forms of MS, starting treatment with a DMT early in the disease course is associated with better long-term outcomes than delaying treatment (**Figure 3**).²⁶

- **Explain the benefits of early intervention with a DMT**, the likely consequences of inadequate or suboptimal treatment, and the goal of minimizing disease activity while optimizing safety.
- Assess and identify areas of concern in treatment adherence and help to develop individualized plans to promote adherence to treatments.




Figure 3. Early intervention with a DMT in people with MS and CIS is thought to give the best long-term outcomes. CIS, clinically isolated syndrome; DMT; disease-modifying therapy.

Decisions about DMTs should be shared and well informed

Shared decision-making is a collaborative process in which clinical evidence and the values and preferences of the person with MS are taken into account. Numerous DMTs with different mechanisms of action are available for the treatment of MS. Each is associated with a particular set of potential benefits, possible side effects and safety concerns. When making treatment decisions, all parties should consider various factors, including employment status, family planning, lifestyle factors, likely adherence to therapy, attitude to risk, aversion to or physical limitations affecting self-injection, and existing comorbidities. Choosing the most appropriate DMT should be a shared decision between the person with MS and their healthcare professionals.

- Help to select the optimal DMT for the individual person with MS, by discussing with them the mechanism of action, relative effectiveness, convenience and side effects of the treatments available in your region.
- Provide evidence-based resources and tools to help people with MS and their families understand the benefits and risks of the various treatment options available.
- **Ensure a shared decision-making process** about options for initiating or switching DMTs that includes dialogue between people with MS and their healthcare professionals.
- Encourage your colleagues and people with MS to consider the full range of DMTs available in your region, to maximize the opportunities for finding the optimal treatment for each individual.

Regular monitoring is central to managing MS

Monitoring MS disease activity to evaluate treatment effectiveness is key to maximizing lifelong brain health. **Figure 4** shows both the clinical and subclinical indicators of MS disease activity that can be monitored in clinical practice.




Figure 4. Monitoring disability progression and relapses can be supplemented by assessment of other measures of disease activity.

Neurofilaments are released when nerve damage occurs; blood neurofilament levels have the potential to be used as an indicator of subclinical disease.

MRI, magnetic resonance imaging.
Reproduced and adapted with permission, from Giovannoni G. Biomarkers in MS.
European Federation of Neurological
Societies/European Neurological Society Joint
Congress of Neurology, 31 May–3 June 2014,
Istanbul, Turkey. © Gavin Giovannoni 2014.

All disease activity damages tissue in the central nervous system, even if there is no evidence of clinical relapse or disability progression. Regularly monitoring disease activity using MRI can give an early warning that MS is not responding well to treatment; disease activity in the form of lesions and brain tissue loss can predict relapses and disability progression.²⁶ MRI or clinical evidence that disease activity is poorly controlled should prompt discussion about the possibility of switching to a DMT with a different mechanism of action (**Figure 5**).




Figure 5. Monitoring is crucial to identifying a suboptimal response to treatment and enabling timely switching to a different disease-modifying therapy. X, Y and Z represent DMT options. DMT, disease-modifying therapy. Reproduced and adapted with permission from Gavin Giovannoni from Personalizing treatment choice. International MS Physician Summit, 22–23 March 2014, Prague, Czech Republic. © Gavin Giovannoni 2014.

What can you do in your nursing practice?

- Encourage people with MS to monitor their disease by keeping an MS diary or using a monitoring app to record factors that affect their health and well-being, such as symptoms, side effects and other diseases, and facilitate open disclosure.
- Participate in the development and implementation of strategies that support active monitoring of disease activity and of DMT safety in people with MS; this will help with rapid identification of suboptimal treatment.
- Act swiftly on suboptimal control of disease activity by initiating a discussion about the possibility of switching to a DMT with a different mechanism of action.
- Discuss the possibility of switching to a DMT with a different mechanism of action when clear MRI evidence of disease activity is available, even if there is no clinical evidence of disease activity (relapses or disability progression).
- Actively participate in setting up and maintaining a database to record patient demographics, relapses, neurological evaluations, MRI results and courses of treatment. Databasing provides a tool for monitoring in everyday clinical practice and improving treatment strategies in your service, as well as contributing to creating long-term real-world evidence for MS management.

References

- Colhoun S, Wilkinson C, Izat A et al. Multiple sclerosis and disease modifying therapies: results of two UK surveys on factors influencing choice. Br J Neurosci Nurs 2015;11:7–13.
- De Stefano N, Airas L, Grigoriadis N et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Druas 2014;28:147–56.
- 3. De Stefano N, Stromillo ML, Giorgio A *et al*. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2016;87:93–9.
- 4. Rocca MA, Filippi M. Functional MRI in multiple sclerosis. *J Neuroimaging* 2007;17 Suppl 1:s36–41.
- Rocca MA, Mezzapesa DM, Falini A et al. Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2003;18:847–55.
- Barkhof F, Scheltens P, Frequin ST et al. Relapsingremitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159:1041–7.
- Kappos L, Moeri D, Radue EW et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964–9.
- 8. Filippi M, Rocca MA. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. *J Neurol* 2005;252 Suppl 5:16–24.
- 9. Kappus N, Weinstock-Guttman B, Hagemeier J et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2016;87:181–7.

- D'Hooghe MB, Nagels G, Bissay V et al. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 2010;16:773–85.
- 11. Pittas F, Ponsonby AL, van der Mei IA *et al.* Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. *J Neurol* 2009;256:577–85.
- 12. Ozcan ME, Ince B, Bingol A *et al.* Association between smoking and cognitive impairment in multiple sclerosis. *Neuropsychiatr Dis Treat* 2014;10:1715–19.
- Jick SS, Li L, Falcone GJ et al. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol 2015;262:2033–41.
- 14. Prakash RS, Snook EM, Motl RW *et al.* Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. *Brain Res* 2010;1341:41–51.
- Sumowski JF, Rocca MA, Leavitt VM et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology 2014;82:1776–83.
- 16. Pinter D, Sumowski J, DeLuca J *et al.* Higher education moderates the effect of T2 lesion load and third ventricle width on cognition in multiple sclerosis. *PLoS One* 2014;9:e87567.
- 17. Modica CM, Bergsland N, Dwyer MG *et al.* Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. *Mult Scler* 2016;22:36–42.
- Sumowski JF, Chiaravalloti N, Wylie G et al. Cognitive reserve moderates the negative effect of brain atrophy on cognitive efficiency in multiple sclerosis. J Int Neuropsychol Soc 2009;15:606–12.
- 19. Sumowski JF, Wylie GR, Chiaravalloti N *et al.* Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis. *Neurology* 2010;74:1942–5.

- Tettey P, Simpson S, Jr., Taylor BV et al. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci 2014;347:23–33.
- Marrie RA, Rudick R, Horwitz R et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. *Neurology* 2010;74:1041–7.
- 22. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. *Medscape J Med* 2008;10:225.
- Remington G, Rodriguez Y, Logan D et al. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care 2013:15:36–45.

- de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis and its treatment. *Patient Prefer Adherence* 2012;6:263–73.
- 25. Bunz TJ, Xu C, Regine ML *et al.* Clinical and economic impact of five-year adherence to disease-modifying therapies in a commercially insured multiple sclerosis population. *Value Health* 2013;16:A109.
- Giovannoni G, Butzkueven H, Dhib-Jalbut S et al.
 Brain health: time matters in multiple sclerosis. Mult
 Scler Relat Disord 2016;9 Suppl 1:S5–S48.

Further resources and training for nursing professionals with an interest in MS

International Organization of MS Nurses (IOMSN; www.iomsn.org) is the largest nursing organization specializing in MS and provides free resources on all aspects of MS nursing.

MS Nurse Professional (www.msnursepro.org) is a European-focused, e-learning training curriculum for nurses beginning their career in the field of MS. It is led by the European Multiple Sclerosis Platform (EMSP) in collaboration with IOMSN and RIMS (European Network of Rehabilitation in Multiple Sclerosis).

MS Nurses International Certifications Board (www.msnicb.org) offers certification by examination for nursing professionals providing care in MS and provides resources for further learning.

MS Brain Health has more free resources online at www.msbrainhealth.org.

Acknowledgements

Preparation of the report *Brain health: time matters in multiple sclerosis* from which this document has been derived was funded by an educational grant from F. Hoffmann-La Roche, who had no influence on the content.

MS Brain Health activities and supporting materials have been funded by grants from AbbVie, Actelion Pharmaceuticals and Sanofi Genzyme, and by educational grants from Biogen, F. Hoffmann-La Roche, Merck KGaA and Novartis, all of whom had no influence on the content. Support for the independent writing and editing of this publication was provided by Oxford PharmaGenesis, Oxford, UK.

The authors thank Michele Messmer Uccelli (Italian MS Society, Genoa, Italy) for consultation on this nursing resource.



© 2017 Oxford PharmaGenesis Ltd. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

"Nurses play a crucial role in MS. Wherever they are in the world, this concise publication offers them clear guidance on how to provide even better advice in areas such as early treatment, monitoring and maintaining brain health, and healthy living, all of which can influence quality of life for people with MS."

Peer Baneke, Multiple Sclerosis International Federation

> "This report encompasses the ongoing challenges faced by people with MS and presents realistic strategies for improving patient care."

Samantha Colhoun, UK Multiple Sclerosis Specialist Nurse Association

Nursing resource authors

Ms Jodi Haartsen

MS Specialist Nurse, Eastern Health MS Service, Eastern Health, Box Hill, VIC, Australia

Dr Aliza Ben-Zacharia

MS Specialist Nurse, Mount Sinai Medical Center, New York, NY, USA

Professor Helmut Butzkueven

Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia

Ms Kathleen Costello

MS Specialist Nurse and Vice President, Healthcare Access, National Multiple Sclerosis Society, New York, NY, USA

Professor Suhayl Dhib-Jalbut

Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

Professor Gavin Giovannoni

Queen Mary University London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK

Ms June Halper

MS Specialist Nurse, International Organization of MS Nurses, Hackensack, NJ, USA

Professor Jeremy Hobart

Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK

Dr Gisela Kobelt

European Health Economics, Mulhouse, France

Ms Vicki Matthews

MS Specialist Nurse and Integrative Counsellor, RIMS (European Network for Rehabilitation in Multiple Sclerosis), Southampton, UK

Mr George Pepper

Shift.ms, Leeds, UK

Dr Maria Pia Sormani

Biostatistics Unit, University of Genoa, Genoa, Italy

Mr Christoph Thalheim

Patient Advocate in Multiple Sclerosis, Brussels, Belgium

Professor Anthony Traboulsee

Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Professor Timothy Vollmer

Department of Neurology, University of Colorado Denver, Aurora, CO, USA

